Vertex Pharmaceuticals 10K 2004 Annual report | VRTX Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abnormally, absolute, ACA, anemia, anniversary, AnorMed, appeal, Asymptomatic, ATPase, Australian, Avalon, AWP, baseline, Bonn, byScientific, Canadian, cardiac, cardiology, case, CFFT, challenging, chemotherapeutic, civil, CMS, colon, communicated, community, comparison, compatible, compliant, constant, contrary, COSO, counteract, criminal, CRP, Darmstadt, Dentsply, deteriorate, discriminate, durable, ECG, ectopy, eighteen, eleven, EMD, Endocrinology, erode, ESPP, eve, exceeded, extra, false, fatigue, feasible, fee, foot, forecasted, foregoing, Framework, gave, Graham, Hartmann, HHS, Holter, Ia, Ib, Icagen, immunodeficiency, imposition, improperly, inflated, inherent, inhibitory, inInternal, inspection, insufficient, interval, intrinsically, isolated, KGaA, Kingdom, Leader, leadership, legislation, legislative, liable, licensee, lucrative, lymphoid, Macalester, magazine, magnitude, matthew, median, Medicaid, medicare, METRO, microbiology, Mitsubishi, mouse, movement, mutated, myelocytic, myeloid, NaV, Nicholson, open, OSI, Oversight, overstated, owe, pancreatic, passage, path, PCI, peginterferon, pertain, phototherapy, point, pre, prescription, prevalent, promulgated, pSivida, QT, ranitidine, rata, redacted, redirection, refine, REFORM, refractory, reinforce, reinforced, remission, repaid, replicon, revert, routine, salary, Shire, silent, simply, slater, spending, stent, stop, successor, summarized, supervision, survival, Tarceva, thein, Thompson, timetable, Tommy, transcriptional, transient, Treadway, unacceptable, unauthorized, unchanged, unclear, undergoing, upregulated, Valeant, ve, ventricular, Victor, virologic, virology, week, Wholesale, withdrawal, withdrawn, xenograft, Zantac

Removed: Aldrich, Alzheimer, anakinra, apoptotic, applying, appraisal, Asian, assuming, banking, begin, Buchanan, CA, Canada, Celebrex, celecoxib, characterizing, Cilag, coincident, complaint, contest, contesting, death, dedicated, defer, degenerative, delivery, downstream, erosion, etanercept, extensively, extinguishment, extraordinary, fluorescence, gained, genome, genomescreen, Gill, Gold, hired, hybrid, Iain, ibuprofen, impeding, inconvenient, infliximab, interpret, inventor, investing, issuing, Johnson, kind, knockout, Madison, main, mapping, merit, methotrexate, microplate, Motrin, mutual, nearby, neurodegenerative, operation, optimizing, Oregon, painful, Parkinson, partnered, patented, pathway, poorly, presently, programmed, protective, reached, recording, Regional, remeasured, remeasurement, replacement, repressed, retention, retroactively, Richard, run, scanning, Scotland, soft, solved, Southeast, St, subfamily, surgery, surrendered, surrogate, swelling, Switzerland, Tim, TNF, UK, ultra, venture, warrant, Wisconsin, Zug

Named Executive Officer		2005 Annual Base Salary Rate Effective February 7, 2005
Dr. Joshua Boger		$547,319
Dr. Vicki Sato		$459,747
Dr. N. Anthony Coles		$383,352
Dr. Peter Mueller		$406,952
Mr. Ian Smith		$360,003

Vertex Pharmaceuticals (VRTX) 10-K2004 FY Annual report

Content analysis